ALSO NOTED: NBTY buys Solgar; Ind-Swift expanding; Shire gets new Adderall letter; and much more...

> NBTY is buying Wyeth's Solgar Vitamin and Herb for $115 million. Story

> India's Ind-Swift is expanding its manufacturing operations. Article

> The UK's Shire Pharmaceuticals has received a second letter from Teva covering an amendment to its ANDA on a generic version of Adderall XR. Story

> Toronto-based Lorus says its cancer drug Virulizin has been granted orphan drug status in the European Union. Release

> Evotec has received its first milestone from its partnership with Boehringer Ingelheim. Release

> San Diego-based TorreyPines Therapeutics has filed an IND for NGX267, the first of several compounds in the company's product pipeline that are designed to treat Alzheimer's disease. Release

And Finally... The New York Times examines the widespread incidence of shingles and breakthrough research on a vaccine that could cure it for a majority of patients. Story

Suggested Articles

Pfizer licensed the drugs, gamma secretase inhibitor nirogacestat and MEK inhibitor mirdametinib, to SpringWorks in 2017.

The company, which was co-founded by Jim Mellon, has reeled in $165 million in 18 months to establish itself at the forefront of the longevity field.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.